Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2510 Plus Chemotherapy in First-Line NSCLC and TNBC
NCT06746870Phase 2Not yet recruiting
- Sponsor
- ImmuneOnco
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
01
Overview
Phase 2, open-label trial of IMM2510 in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) (3 cohorts), sponsored by ImmuneOnco. Primary endpoints: Preliminary clinical efficacy of IMM2510 in combination with chemotherapy in NSCLC at 96 weeks and Preliminary clinical efficacy of IMM2510 in combination with nab-paclitaxel in TNBC at 96 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
IMM2510
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06746870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06746870.